Treatment of childhood-onset systemic lupus erythematosus (cSLE) has been limited to traditional immunomodulators until the recent introduction of biologic therapy. Knowledge of these agents and their role in treatment is necessary for the pediatric pharmacist to develop an effective and safe therapeutic regimen and monitoring plan. This session will focus on the role of biologic therapy in the management of cSLE using interactive patient cases and in-depth evaluation of the current literature in order to equip the pediatric pharmacist with the necessary knowledge and tools to integrate into clinical practice.   

This activity is approved for Board Certified Pediatric Pharmacist (BCPPS) recertification credit. 

The BCPPS Clinical Sessions are part of the professional development program for the recertification of board-certified Pediatric Pharmacist by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCPPS recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the Clinical Sessions posttests will be available on December 18, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCPPS posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 15, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 16, 2025. 

1. Examine current non-biologic standards of care for childhood-onset systemic lupus erythematosus.

2. Evaluate current literature for the role and integration of biologic therapy in the management of childhood-onset systemic lupus erythematosus.

3. Develop strategies to manage biologic therapy for hospital and health-system formularies.